WO2000008015A3 - Fsh mimetics for the treatment of infertility - Google Patents

Fsh mimetics for the treatment of infertility Download PDF

Info

Publication number
WO2000008015A3
WO2000008015A3 PCT/US1999/017755 US9917755W WO0008015A3 WO 2000008015 A3 WO2000008015 A3 WO 2000008015A3 US 9917755 W US9917755 W US 9917755W WO 0008015 A3 WO0008015 A3 WO 0008015A3
Authority
WO
WIPO (PCT)
Prior art keywords
infertility
treatment
fsh
derivatives
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017755
Other languages
French (fr)
Other versions
WO2000008015A2 (en
Inventor
Tayer Nabil El
Adulla Reddy
David Buckler
Sharad Magar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99939686A priority Critical patent/EP1102763B1/en
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Priority to AT99939686T priority patent/ATE279407T1/en
Priority to AU53931/99A priority patent/AU772373B2/en
Priority to DK99939686T priority patent/DK1102763T3/en
Priority to CA002339018A priority patent/CA2339018A1/en
Priority to DE69921147T priority patent/DE69921147T2/en
Priority to IL14106399A priority patent/IL141063A/en
Priority to JP2000563648A priority patent/JP4511042B2/en
Publication of WO2000008015A2 publication Critical patent/WO2000008015A2/en
Publication of WO2000008015A3 publication Critical patent/WO2000008015A3/en
Anticipated expiration legal-status Critical
Priority to AU2004202858A priority patent/AU2004202858B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides non-peptidic amino derivatives, their therapeutic use as well as pharmaceutical compositions that possess activity as Follicle Stimulating Hormone (FSH) agonists and are useful in the treatment of infertility. In particular, the invention provides cyclic and acyclic alpha- and beta-aminocarboxamides, more particularly tetrahydroisoquinolinecarboxamides, piperidinecarboxamides, pyrrolidinecarboxamides, and 2-amino-3-carboxamidopyridine derivatives.
PCT/US1999/017755 1998-08-07 1999-08-05 Fsh mimetics for the treatment of infertility Ceased WO2000008015A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2000563648A JP4511042B2 (en) 1998-08-07 1999-08-05 FSH mimics for the treatment of infertility
AT99939686T ATE279407T1 (en) 1998-08-07 1999-08-05 FSH MIMETICS FOR THE TREATMENT OF INFERTILITY
AU53931/99A AU772373B2 (en) 1998-08-07 1999-08-05 FSH mimetics for the treatment of infertility
DK99939686T DK1102763T3 (en) 1999-08-05 1999-08-05 FSH mimetics for the treatment of infertility
CA002339018A CA2339018A1 (en) 1998-08-07 1999-08-05 Fsh mimetics for the treatment of infertility
EP99939686A EP1102763B1 (en) 1998-08-07 1999-08-05 Fsh mimetics for the treatment of infertility
IL14106399A IL141063A (en) 1998-08-07 1999-08-05 Derivatives of pyrrolidine-2-carboxylic acid and piperidine-2-carboxylic acids and pharmaceutical compositions comprising said derivatives for treating infertility
DE69921147T DE69921147T2 (en) 1998-08-07 1999-08-05 FSH MIMETIKA FOR THE TREATMENT OF INFERTILITY
AU2004202858A AU2004202858B2 (en) 1998-08-07 2004-06-25 FSH mimetics for the treatment of infertility

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9571298P 1998-08-07 1998-08-07
US60/095,712 1998-08-07

Publications (2)

Publication Number Publication Date
WO2000008015A2 WO2000008015A2 (en) 2000-02-17
WO2000008015A3 true WO2000008015A3 (en) 2000-05-11

Family

ID=22253270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017755 Ceased WO2000008015A2 (en) 1998-08-07 1999-08-05 Fsh mimetics for the treatment of infertility

Country Status (12)

Country Link
US (3) US6235755B1 (en)
EP (1) EP1102763B1 (en)
JP (1) JP4511042B2 (en)
AR (1) AR021755A1 (en)
AT (2) ATE279407T1 (en)
AU (1) AU772373B2 (en)
CA (1) CA2339018A1 (en)
DE (2) DE69921147T2 (en)
ES (2) ES2228084T3 (en)
IL (1) IL141063A (en)
PT (2) PT1102763E (en)
WO (1) WO2000008015A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071587B2 (en) 2009-05-27 2011-12-06 N. V. Organon (Dihydro)imidazoiso[5,1-A]quinolines

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025355A (en) 1997-05-19 2000-02-15 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
US6297233B1 (en) 1999-02-09 2001-10-02 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
ES2261404T3 (en) * 2000-03-27 2006-11-16 Applied Research Systems Ars Holding N.V. USED PIRROLIDINE DERIVATIVES AS BAX INHIBITORS.
DK1268418T3 (en) * 2000-03-27 2006-09-25 Applied Research Systems Pharmaceutically active pyrrolidine derivatives as Bax inhibitors
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US6900213B2 (en) 2001-01-19 2005-05-31 Pharmacopeia Drug Discovery, Inc. Bisaryl derivatives having FSH modulatory activity
DE60201415T2 (en) * 2001-01-19 2006-02-09 Pharmacopeia, Inc. BISARYL DERIVATIVES WITH FSH RECEPTOR MODULATING ACTIVITY
WO2002068409A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US7259157B2 (en) 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
CZ20032990A3 (en) * 2001-05-05 2004-04-14 Smithkline Beecham P. L. C. N-aroyl cyclic amines
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
RU2347570C2 (en) * 2001-07-02 2009-02-27 Н.В.Органон Tetrahydroquinoline derivatives
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
UA87433C2 (en) * 2001-10-22 2009-07-27 Еплайд Рісьорч Системз Ерс Холдінг Н.В. Gonadotropines for stimulation of folliculogenesis
ES2399047T3 (en) * 2002-09-20 2013-03-25 Merck Serono Sa Piperazine derivatives and use procedure
CN100386318C (en) * 2002-12-20 2008-05-07 欧加农股份有限公司 Tetrahydroquinoline derivatives and their use as FSH receptor modulators
CN100404508C (en) * 2002-12-20 2008-07-23 欧加农股份有限公司 Tetrahydroquinoline derivatives
TWI306855B (en) * 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
UA88879C2 (en) * 2003-09-02 2009-12-10 Эплайд Рисерч Системз Эрс Холдинг Н.В. Fsh glycosylation mutant
BRPI0507174A (en) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc hormone-stimulating heterodimeric fc (fsh-fc) fusion proteins for the treatment of infertility
US7691848B2 (en) 2005-03-02 2010-04-06 Wyeth Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
US20100022582A1 (en) * 2005-03-10 2010-01-28 Kenji Takahashi Tetrahydroisoquinoline Compound and Medicinal Use Thereof
UA92008C2 (en) 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
DK1879866T3 (en) 2005-05-04 2011-06-06 Organon Nv dihydropyridine derivatives
UA92007C2 (en) 2005-05-04 2010-09-27 Н.В. Органон 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives the treatment of infertility
UA92009C2 (en) 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-0X0-l,4,5,6,7,8-HEXAHYDR0QЛIN0LINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
MX2007014085A (en) 2005-05-12 2008-02-07 Wyeth Corp Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (fsh-r) antagonists.
WO2006135687A1 (en) 2005-06-09 2006-12-21 Wyeth Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
EP2018384A2 (en) * 2006-05-17 2009-01-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Pyrimidine low molecular weight ligands for modulating hormone receptors
JP5448164B2 (en) 2006-07-28 2014-03-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
BRPI0806365B8 (en) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc compound, use of compound, pharmaceutical composition and use of pharmaceutical composition
WO2009045440A1 (en) 2007-10-01 2009-04-09 Lixte Biotechnology Holdings, Inc. Hdac inhibitors
JP5492092B2 (en) 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
TW200944523A (en) * 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
US8178568B2 (en) 2008-07-10 2012-05-15 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the CB2 receptor
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8058268B2 (en) 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8048899B2 (en) 2008-09-25 2011-11-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010083328A2 (en) 2009-01-14 2010-07-22 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
JP5705748B2 (en) 2009-02-18 2015-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Heterocyclic compounds that modulate the CB2 receptor
TWI461426B (en) * 2009-05-27 2014-11-21 Merck Sharp & Dohme (dihydro)imidazoiso[5,1-a]quinolines
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8383615B2 (en) 2009-06-16 2013-02-26 Boehringer Ingelheim International Gmbh Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
US8431564B2 (en) 2009-07-29 2013-04-30 Merck Sharp & Dohme B.V. Ring-annulated dihydropyrrolo[2,1-α]isoquinolines
TW201116531A (en) 2009-07-29 2011-05-16 Organon Nv Ring-annulated dihydropyrrolo[2,1-a]isoquinolines
TW201116515A (en) * 2009-07-31 2011-05-16 Organon Nv Dihydrobenzoindazoles
RU2569063C2 (en) 2009-09-01 2015-11-20 Катабэйсис Фармасьютикалз, Инк. Conjugates of fatty acids and niacin and application thereof
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
EP2480544A1 (en) 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
JP2013517271A (en) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
EP2595959B1 (en) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
CA2837524C (en) 2011-07-01 2019-08-20 Merck Patent Gmbh Dihydropyrazoles
JP6162694B2 (en) 2011-07-18 2017-07-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Benzamides
CN104080784B (en) * 2012-01-10 2017-07-18 默克专利有限公司 Heterocyclic carbamate derivatives as follicular stimulating hormone conditioning agent
CN104114544A (en) 2012-02-08 2014-10-22 默克专利有限公司 Deuterated thiazolidinone analogs useful as follicle stimulating hormone receptor agonists
CA2909160C (en) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
EP3013823B1 (en) 2013-06-24 2017-11-01 Merck Patent GmbH Imidazole compounds as modulators of fshr and uses thereof
JP6625973B2 (en) 2013-06-24 2019-12-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Pyrazole compounds as modulators of FSHR and uses thereof
US11433047B2 (en) 2015-10-09 2022-09-06 Neurotheryx Canada Ltd. Pharmaceutical compositions comprising one or more pyrone compounds, and their use for treating inflammatory and neurodegenerative diseases
WO2018107004A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
US10729689B2 (en) * 2017-10-26 2020-08-04 University Of Puerto Rico Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents
PE20221040A1 (en) 2019-10-25 2022-06-17 Gilead Sciences Inc GLP-1R MODULATING COMPOUNDS
CA3168543A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022109182A1 (en) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
PL4271672T3 (en) 2021-04-21 2026-04-20 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds
WO2024184461A2 (en) 2023-03-08 2024-09-12 Ferring B.V. Small molecule fsh receptor modulators
CN117510475A (en) * 2023-11-01 2024-02-06 江苏缘龙医院管理有限责任公司 Musashi protein inhibitors that interfere with RNA-protein interactions and their applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071836A (en) * 1988-12-14 1991-12-10 Hoechst Aktiengesellschaft Competitive gonadoliberin antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947569A (en) * 1972-04-12 1976-03-30 American Home Products Corporation Process for preparing the releasing hormone of luteinizing hormone (LH) and of follicle stimulating hormone (FSH), salts and compositions thereof, and intermediates therefor
JPS5331669A (en) * 1976-09-06 1978-03-25 Kissei Pharmaceut Co Ltd Novel n-acylpiperidinecaroxyanilide derivatives and their preparation
US4800432A (en) * 1986-10-24 1989-01-24 The Grass Valley Group, Inc. Video Difference key generator
DE3636278A1 (en) * 1986-10-24 1988-05-05 Hoechst Ag HERBICIDES BASED ON CYCLIC (ALPHA) -IMINOCARBON ACID ANILIDES AND NEW (ALPHA) -IMINOCARBONIC ACID ANILIDES AND METHOD FOR THE PRODUCTION THEREOF
US5071823A (en) 1988-10-12 1991-12-10 Mitsubishi Paper Mills Limited Image-receiving sheet for transfer recording
DE59309867D1 (en) * 1992-09-03 1999-12-16 Boehringer Ingelheim Pharma NEW AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US5455229A (en) * 1992-12-23 1995-10-03 Eli Lilly And Company Method for minimizing and containing ischemic and reperfusion injury
PE45195A1 (en) * 1994-03-03 1996-01-17 Boehringer Ingelheim Kg DERIVATIVE OF AMINO ACID, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT
AU753540B2 (en) * 1998-03-05 2002-10-24 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071836A (en) * 1988-12-14 1991-12-10 Hoechst Aktiengesellschaft Competitive gonadoliberin antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071587B2 (en) 2009-05-27 2011-12-06 N. V. Organon (Dihydro)imidazoiso[5,1-A]quinolines

Also Published As

Publication number Publication date
AU772373B2 (en) 2004-04-22
EP1102763B1 (en) 2004-10-13
ATE329911T1 (en) 2006-07-15
US6235755B1 (en) 2001-05-22
PT1380582E (en) 2006-08-31
AR021755A1 (en) 2002-08-07
US20020147345A1 (en) 2002-10-10
ATE279407T1 (en) 2004-10-15
AU5393199A (en) 2000-02-28
DE69921147D1 (en) 2004-11-18
US6653338B2 (en) 2003-11-25
ES2261844T3 (en) 2006-11-16
EP1102763A2 (en) 2001-05-30
CA2339018A1 (en) 2000-02-17
DE69921147T2 (en) 2005-02-24
IL141063A (en) 2005-06-19
DE69931975D1 (en) 2006-07-27
IL141063A0 (en) 2002-02-10
ES2228084T3 (en) 2005-04-01
US6423723B1 (en) 2002-07-23
WO2000008015A2 (en) 2000-02-17
DE69931975T2 (en) 2006-10-05
PT1102763E (en) 2005-01-31
JP2002522433A (en) 2002-07-23
JP4511042B2 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
GB2288732B (en) Pharmaceutical compositions
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
MX9707431A (en) Protein kinase c inhibitors.
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
MXPA04001524A (en) Rapamycin 29-enols.
BR9811956B1 (en) naphthyridinones and pharmaceutical composition comprising them.
PL339745A1 (en) Agonists of apolipoprotein a-1 and their application in treating dislipidemic disorders
TR199903331T2 (en) Farnesil protein transferase inhibitors.
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
MXPA05002814A (en) Formulation for lipophilic agents.
ZA975443B (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides.
GB2352395A (en) Paroxetine methanesulfonate
PT804252E (en) METALLIC CHELTER AGENTS THAT CONTAINS DIAMOND MONOAMINES AND THIOIS
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
YU13301A (en) Muscarinic agonists and antagonists
SI1546127T1 (en) Novel pyrimidineamide derivatives and the use thereof
GB0111186D0 (en) Novel compounds
WO2002070464A3 (en) Hydrazones and their therapeutic use
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
AU6469401A (en) Pharmaceutically active compounds and methods of use
CA2388910A1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
NZ240481A (en) Aminosulphonyl urea derivatives and pharmaceutical compositions
MXPA02000330A (en) Neurotrophic pyrrolidines and piperidines, and related compositions and methods.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 141063

Country of ref document: IL

Ref document number: 53931/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2339018

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2339018

WWE Wipo information: entry into national phase

Ref document number: 1999939686

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999939686

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 53931/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999939686

Country of ref document: EP